{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:12:43Z","timestamp":1790208763594,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["25ZR1401381"],"award-info":[{"award-number":["25ZR1401381"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M733629"],"award-info":[{"award-number":["2023M733629"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["22YF1457600"],"award-info":[{"award-number":["22YF1457600"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bmc.2026.118552","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T16:17:07Z","timestamp":1768061827000},"page":"118552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapeutic targeting of CDK12: a medicinal chemistry perspective"],"prefix":"10.1016","volume":"135","author":[{"given":"Feifei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxue","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuanxin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0010","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/ncb1109-1275","article-title":"Cyclin-dependent kinases: a family portrait","volume":"11","author":"Malumbres","year":"2009","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.bmc.2026.118552_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0209s60","article-title":"The human kinome and kinase inhibition","author":"Duong-Ly","year":"2013","journal-title":"Curr Protoc Pharmacol"},{"issue":"6","key":"10.1016\/j.bmc.2026.118552_bb0020","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/cells9061483","article-title":"CDK12: a potent target and biomarker for human cancer therapy","volume":"9","author":"Liang","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bmc.2026.118552_bb0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"10.1016\/j.bmc.2026.118552_bb0035","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1101\/gad.1968210","article-title":"CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1","volume":"24","author":"Bartkowiak","year":"2010","journal-title":"Genes Dev"},{"issue":"15","key":"10.1016\/j.bmc.2026.118552_bb0040","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.7150\/jca.42849","article-title":"CDK12 promotes papillary thyroid cancer progression through regulating the c-myc\/\u03b2-catenin pathway","volume":"11","author":"Bai","year":"2020","journal-title":"J Cancer"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/21541264.2018.1535211","article-title":"Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium","volume":"10","author":"Greenleaf","year":"2019","journal-title":"Transcription"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188842","article-title":"Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy","volume":"1878","author":"Wu","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"10.1016\/j.bmc.2026.118552_bb0055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bmc.2026.118552_bb0060","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bmc.2026.118552_bb0065","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1634\/theoncologist.2019-0214","article-title":"Pan-cancer analysis of CDK12 loss-of-function alterations and their association with the focal tandem-duplicator phenotype","volume":"24","author":"Sokol","year":"2019","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bmc.2026.118552_bb0070","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0124","article-title":"Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells","volume":"32","author":"Rajan","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bmc.2026.118552_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1747-1028-7-12","article-title":"Cyclin K goes with Cdk12 and Cdk13","volume":"7","author":"Kohoutek","year":"2012","journal-title":"Cell Div"},{"issue":"20","key":"10.1016\/j.bmc.2026.118552_bb0080","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.bmc.2026.118552_bb0085","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201847592","article-title":"CDK12 controls G1\/S progression by regulating RNAPII processivity at core DNA replication genes","volume":"20","author":"Chirackal Manavalan","year":"2019","journal-title":"EMBO Rep"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.celrep.2015.12.025","article-title":"Structural and functional analysis of the Cdk13\/Cyclin K complex","volume":"14","author":"Greifenberg","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2026.118552_bb0095","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/1538-7445.AM2025-7004","article-title":"CT7439 an oral first-in class selective CDK12 and 13 inhibitor and cyclin K degrader: profiling activity and combination efficacy in an ovarian cancer model","volume":"85","author":"Ashwani","year":"2025","journal-title":"Cancer Res"},{"issue":"Pt 14","key":"10.1016\/j.bmc.2026.118552_bb0100","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1242\/jcs.114.14.2591","article-title":"CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles","volume":"114","author":"Ko","year":"2001","journal-title":"J Cell Sci"},{"issue":"7","key":"10.1016\/j.bmc.2026.118552_bb0105","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1128\/MCB.26.7.2736-2745.2006","article-title":"Identification and characterization of the CDK12\/cyclin L1 complex involved in alternative splicing regulation","volume":"26","author":"Chen","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"22","key":"10.1016\/j.bmc.2026.118552_bb0110","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1128\/MCB.06267-11","article-title":"Interaction of cyclin-dependent kinase 12\/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II","volume":"32","author":"Cheng","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"30","key":"10.1016\/j.bmc.2026.118552_bb0115","doi-asserted-by":"crossref","first-page":"25344","DOI":"10.1074\/jbc.M111.321760","article-title":"Cyclin K-containing kinase complexes maintain self-renewal in murine embryonic stem cells","volume":"287","author":"Dai","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118552_bb0120","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1038\/ncomms4505","article-title":"The structure and substrate specificity of human Cdk12\/Cyclin K","volume":"5","author":"B\u00f6sken","year":"2014","journal-title":"Nat Commun"},{"issue":"6266","key":"10.1016\/j.bmc.2026.118552_bb0125","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1126\/science.aad2338","article-title":"RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II","volume":"350","author":"Yu","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bmc.2026.118552_bb0130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/MCB.01426-14","article-title":"Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing","volume":"35","author":"Liang","year":"2015","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/acs.jmedchem.1c01719","article-title":"Discovery of cysteine-targeting covalent protein kinase inhibitors","volume":"65","author":"Lu","year":"2022","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.bmc.2026.118552_bb0140","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1021\/acs.jmedchem.9b01929","article-title":"Discovery of MFH290: a potent and highly selective covalent inhibitor for cyclin-dependent kinase 12\/13","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1096\/fasebj.14.2.231","article-title":"The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains","volume":"14","author":"Kay","year":"2000","journal-title":"FASEB J"},{"issue":"19","key":"10.1016\/j.bmc.2026.118552_bb0150","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/anie.200400618","article-title":"Recognition of proline-rich motifs by protein-protein-interaction domains","volume":"44","author":"Ball","year":"2005","journal-title":"Angew Chem Int Ed Eng"},{"key":"10.1016\/j.bmc.2026.118552_bb0155","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.2741\/3053","article-title":"The SH3 domain--a family of versatile peptide- and protein-recognition module","volume":"13","author":"Kaneko","year":"2008","journal-title":"Front Biosci"},{"issue":"Pt 7","key":"10.1016\/j.bmc.2026.118552_bb0160","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1242\/jcs.114.7.1253","article-title":"SH3 domains: complexity in moderation","volume":"114","author":"Mayer","year":"2001","journal-title":"J Cell Sci"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0165","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbrc.2017.06.121","article-title":"Structure of an unconventional SH3 domain from the postsynaptic density protein Shank3 at ultrahigh resolution","volume":"490","author":"Ponna","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.bmc.2026.118552_bb0170","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/emboj\/16.9.2376","article-title":"FBP WW domains and the Abl SH3 domain bind to a specific class of proline-rich ligands","volume":"16","author":"Bedford","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.bmc.2026.118552_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/srep17122","article-title":"Structures of the CDK12\/CycK complex with AMP-PNP reveal a flexible C-terminal kinase extension important for ATP binding","volume":"5","author":"Dixon-Clarke","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2026.118552_bb0180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","article-title":"Recent development of CDK inhibitors: an overview of CDK\/inhibitor co-crystal structures","volume":"164","author":"Cheng","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0185","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: an emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/0008-5472.CAN-20-2245","article-title":"Targeting CDK12 for Cancer therapy: function, mechanism, and drug discovery","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4155\/fmc-2020-0240","article-title":"The promise and current status of CDK12\/13 inhibition for the treatment of cancer","volume":"13","author":"Tadesse","year":"2021","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0200","article-title":"CDK12: cellular functions and therapeutic potential of versatile player in cancer. NAR","volume":"2","author":"Pilarova","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bmc.2026.118552_bb0205","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/hmg\/10.7.699","article-title":"The Rb\/E2F pathway and cancer","volume":"10","author":"Nevins","year":"2001","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0210","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41467-018-04258-w","article-title":"Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation","volume":"9","author":"Lei","year":"2018","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.bmc.2026.118552_bb0215","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1101\/gad.200303.112","article-title":"The RNA polymerase II CTD coordinates transcription and RNA processing","volume":"26","author":"Hsin","year":"2012","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0220","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1128\/MCB.01859-07","article-title":"P-TEFb is critical for the maturation of RNA polymerase II into productive elongation in vivo","volume":"28","author":"Ni","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.bmc.2026.118552_bb0225","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41580-018-0010-5","article-title":"Born to run: control of transcription elongation by RNA polymerase II","volume":"19","author":"Chen","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrg3662","article-title":"Coupling mRNA processing with transcription in time and space","volume":"15","author":"Bentley","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0235","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1021\/cr400071f","article-title":"The RNA polymerase II carboxy-terminal domain (CTD) code","volume":"113","author":"Eick","year":"2013","journal-title":"Chem Rev"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0240","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1128\/MCB.01157-14","article-title":"Cyclin-dependent kinase 12 increases 3\u2032 end processing of growth factor-induced c-FOS transcripts","volume":"35","author":"Eifler","year":"2015","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.bmc.2026.118552_bb0245","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a003707","article-title":"Spliceosome structure and function","volume":"3","author":"Will","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0250","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1093\/nar\/gkx187","article-title":"CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion","volume":"45","author":"Tien","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0255","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1074\/jbc.M114.612226","article-title":"Expression, purification, and identification of associated proteins of the full-length hCDK12\/CyclinK complex","volume":"290","author":"Bartkowiak","year":"2015","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118552_bb0260","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1242\/dev.074070","article-title":"The regulation of glial-specific splicing of neurexin IV requires HOW and Cdk12 activity","volume":"139","author":"Rodrigues","year":"2012","journal-title":"Development"},{"issue":"7\u20138","key":"10.1016\/j.bmc.2026.118552_bb0265","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1101\/gad.322339.118","article-title":"CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability","volume":"33","author":"Choi","year":"2019","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0270","first-page":"2289","article-title":"Cdk12 regulates neurogenesis and late-arising neuronal migration in the developing cerebral cortex","volume":"27","author":"Chen","year":"2017","journal-title":"Cereb Cortex"},{"issue":"5","key":"10.1016\/j.bmc.2026.118552_bb0275","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1093\/nar\/gkv101","article-title":"Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12\/CycK complex","volume":"43","author":"Ekumi","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"7734","key":"10.1016\/j.bmc.2026.118552_bb0280","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0285","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41467-019-09703-y","article-title":"CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation","volume":"10","author":"Krajewska","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0290","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1568009619666191118113220","article-title":"CDK12 promotes breast cancer progression and maintains stemness by activating c-myc\/\u03b2 -catenin signaling","volume":"20","author":"Peng","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.bmc.2026.118552_bb0295","first-page":"511","article-title":"Research progress of PROTAC-degraded CDKs in the treatment of breast cancer","volume":"17","author":"Zhao","year":"2025","journal-title":"Breast Cancer (Dove Med. Press)"},{"issue":"24","key":"10.1016\/j.bmc.2026.118552_bb0300","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426909122","article-title":"Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma","volume":"122","author":"Tien","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118552_bb0305","article-title":"CDK12 inactivation attenuates prostate cancer progression by inhibiting BNIP3-mediated mitophagy","volume":"2","author":"Huang","year":"2025","journal-title":"Cell Prolif"},{"issue":"13","key":"10.1016\/j.bmc.2026.118552_bb0310","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.1074\/jbc.M114.551143","article-title":"Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly (ADP-ribose) polymerase inhibitors","volume":"289","author":"Joshi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118552_bb0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-017-0033-x","article-title":"The emerging roles of CDK12 in tumorigenesis","volume":"12","author":"Paculov\u00e1","year":"2017","journal-title":"Cell Div"},{"issue":"12","key":"10.1016\/j.bmc.2026.118552_bb0320","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.drudis.2020.09.035","article-title":"CDK12: a potential therapeutic target in cancer","volume":"25","author":"Emadi","year":"2020","journal-title":"Drug Discov Today"},{"issue":"17","key":"10.1016\/j.bmc.2026.118552_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu0847","article-title":"Acute BRCAness induction and AR pathway blockage through CDK12\/7\/9 degradation enhances PARP inhibitor sensitivity in prostate cancer","volume":"11","author":"Gui","year":"2025","journal-title":"Sci Adv"},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0330","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.7150\/ijbs.94568","article-title":"Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer","volume":"20","author":"Liang","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"10","key":"10.1016\/j.bmc.2026.118552_bb0335","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948058","article-title":"CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling","volume":"20","author":"Choi","year":"2019","journal-title":"EMBO Rep"},{"issue":"24","key":"10.1016\/j.bmc.2026.118552_bb0340","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1073\/pnas.1121119109","article-title":"Functional genomics identifies therapeutic targets for MYC-driven cancer","volume":"109","author":"Toyoshima","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0345","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","article-title":"EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma","volume":"33","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"issue":"7353","key":"10.1016\/j.bmc.2026.118552_bb0350","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bmc.2026.118552_bb0355","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","article-title":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","volume":"25","author":"Staaf","year":"2019","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.bmc.2026.118552_bb0360","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.bmc.2026.118552_bb0365","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41589-021-00765-y","article-title":"Discovery and resistance mechanism of a selective CDK12 degrader","volume":"17","author":"Jiang","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2026.118552_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113481","article-title":"Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12\/13 covalent inhibitor with efficacy in Ewing sarcoma","volume":"221","author":"Jiang","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"7511","key":"10.1016\/j.bmc.2026.118552_bb0375","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118552_bb0380","series-title":"Bicyclic amines as CDK12 inhibitors. WO 2023\/107705 Al","author":"Minh","year":"2023"},{"issue":"19","key":"10.1016\/j.bmc.2026.118552_bb0385","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1158\/0008-5472.CAN-22-0222","article-title":"Dual inhibition of CDK12\/CDK13 targets both tumor and immune cells in ovarian cancer","volume":"82","author":"Cheng","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118552_bb0390","unstructured":"Tan L., Li Y., Zhou S.Q., et al. Class of CDK inhibitor based on organic arsine, preparation method and application thereof. WO 2021\/057867, 2021-04-01."},{"issue":"12","key":"10.1016\/j.bmc.2026.118552_bb0395","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41388-022-02210-3","article-title":"SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer","volume":"41","author":"Lin","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0400","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118552_bb0405","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1177\/2472555220973602","article-title":"CDK family PROTAC profiling reveals distinct kinetic responses and cell cycle-dependent degradation of CDK2","volume":"26","author":"Riching","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.bmc.2026.118552_bb0410","series-title":"2-aminopyrimidine compound or salt, preparation method therefor and use thereof. WO 2023\/143482","author":"Wang","year":"2023"},{"key":"10.1016\/j.bmc.2026.118552_bb0415","series-title":"CDK12 degradation inhibitors and uses thereof. CN 118359589,","author":"Li","year":"2024"},{"issue":"13","key":"10.1016\/j.bmc.2026.118552_bb0420","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1039\/D2CS00197G","article-title":"Chasing molecular glue degraders: screening approaches","volume":"51","author":"Domostegui","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0425","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41589-023-01409-z","article-title":"Design principles for cyclin K molecular glue degraders","volume":"20","author":"Kozicka","year":"2024","journal-title":"Nat Chem Biol"},{"issue":"38","key":"10.1016\/j.bmc.2026.118552_bb0430","article-title":"Rational design of CDK12\/13 and BRD4 molecular glue degraders","volume":"64","author":"Zhuang","year":"2025","journal-title":"Angew Chem Int Ed Eng"},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0435","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"10.1016\/j.bmc.2026.118552_bb0440","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1021\/jm800109e","article-title":"Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1","volume":"51","author":"Oumata","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118552_bb0445","article-title":"Small molecule inhibitors of CDK12\/13","author":"Roush","year":"2019","journal-title":"WO"},{"issue":"6","key":"10.1016\/j.bmc.2026.118552_bb0450","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/ar0201198","article-title":"Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials","volume":"36","author":"Meijer","year":"2003","journal-title":"Acc Chem Res"},{"issue":"7824","key":"10.1016\/j.bmc.2026.118552_bb0455","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","article-title":"The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K","volume":"585","author":"S\u0142abicki","year":"2020","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.bmc.2026.118552_bb0460","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1016\/j.bmcl.2007.09.018","article-title":"Versatile templates for the development of novel kinase inhibitors: discovery of novel CDK inhibitors","volume":"17","author":"Dwyer","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.bmc.2026.118552_bb0465","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/ml100051d","article-title":"Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases","volume":"1","author":"Paruch","year":"2010","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"10.1016\/j.bmc.2026.118552_bb0470","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.bmc.2026.118552_bb0475","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1016\/j.bmcl.2013.05.075","article-title":"Development of highly selective casein kinase 1\u03b4\/1\u03b5 (CK1\u03b4\/\u03b5) inhibitors with potent antiproliferative properties","volume":"23","author":"Bibian","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0480","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cmdc.201700695","article-title":"Structure-based design of selective noncovalent CDK12 inhibitors","volume":"13","author":"Johannes","year":"2018","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118552_bb0485","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.chembiol.2017.11.007","article-title":"Overcoming resistance to the THZ series of covalent transcriptional CDK inhibitors","volume":"25","author":"Gao","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0490","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41420-023-01754-x","article-title":"The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma","volume":"9","author":"Houles","year":"2023","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0495","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1038\/s41467-024-50642-0","article-title":"Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118552_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114012","article-title":"Noncovalent CDK12\/13 dual inhibitors-based PROTACs degrade CDK12-cyclin K complex and induce synthetic lethality with PARP inhibitor","volume":"228","author":"Niu","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118552_bb0505","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1039\/D4CB00190G","article-title":"Discovery and design of molecular glue enhancers of CDK12-DDB1 interactions for targeted degradation of cyclin K","volume":"6","author":"Ghosh","year":"2024","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.bmc.2026.118552_bb0510","unstructured":"Thede K., Buchgraber P., Siemeister G., et al. Imidazolotriazines acting on cancers via inhibition of CDK12. WO 2021\/176045, 2021-09-10."},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0515","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1021\/acs.jmedchem.5b01938","article-title":"Multiparameter lead optimization to give an oral checkpoint kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)","volume":"59","author":"Osborne","year":"2016","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.bmc.2026.118552_bb0520","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1021\/acs.jmedchem.8b00683","article-title":"Discovery of 3-benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (CDK12) inhibitors","volume":"61","author":"Ito","year":"2018","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118552_bb0525","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1021\/acs.jmedchem.5c00127","article-title":"Discovery of YJZ5118: a potent and highly selective irreversible CDK12\/13 inhibitor with synergistic effects in combination with Akt inhibition","volume":"68","author":"Yang","year":"2025","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.bmc.2026.118552_bb0530","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","article-title":"Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13","volume":"65","author":"Yang","year":"2022","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.bmc.2026.118552_bb0535","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.bmc.2026.118552_bb0540","doi-asserted-by":"crossref","first-page":"18247","DOI":"10.1021\/acs.jmedchem.4c01596","article-title":"Discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12\/13 PROTAC degrader","volume":"67","author":"Zhou","year":"2024","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118552_bb0545","article-title":"Development of an orally bioavailable CDK12\/13 degrader and induction of synthetic lethality with AKT pathway inhibition","volume":"5","author":"Chang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"7","key":"10.1016\/j.bmc.2026.118552_bb0550","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/jm0305568","article-title":"N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl] methyl] thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent","volume":"47","author":"Misra","year":"2004","journal-title":"J Med Chem"},{"issue":"541","key":"10.1016\/j.bmc.2026.118552_bb0555","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz2415","article-title":"CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model","volume":"12","author":"Ketley","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmc.2026.118552_bb0560","unstructured":"Eric A.M., John T., Noelito T., et al. Treatment of cancer with CDK12\/13 inhibitors. WO2021\/138215, 2021-07-08.2021-07-08."},{"issue":"12","key":"10.1016\/j.bmc.2026.118552_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103799","article-title":"The expanding repertoire of covalent warheads for drug discovery","volume":"28","author":"Mehta","year":"2023","journal-title":"Drug Discov Today"},{"issue":"12","key":"10.1016\/j.bmc.2026.118552_bb0570","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1021\/acs.jcim.7b00553","article-title":"Expanding the armory: predicting and tuning covalent warhead reactivity","volume":"57","author":"Lonsdale","year":"2017","journal-title":"J Chem Inf Model"},{"issue":"4","key":"10.1016\/j.bmc.2026.118552_bb0575","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1021\/acs.jmedchem.4c01616","article-title":"Design, synthesis, and biological evaluation of novel orally available covalent CDK12\/13 dual inhibitors for the treatment of tumors","volume":"68","author":"Lu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118552_bb0580","unstructured":"Lu H.F., Liu Y.T., Wu J.P., et al. Inhibitors of cyclin-dependent kinase (CDK) 12 and\/or CDK13 and uses thereof. WO 2024\/032561, 2024-02-15."},{"key":"10.1016\/j.bmc.2026.118552_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117378","article-title":"Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12\/13","volume":"288","author":"Xia","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"23\u201324","key":"10.1016\/j.bmc.2026.118552_bb0590","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.bmcl.2018.10.020","article-title":"Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy","volume":"28","author":"Rana","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.bmc.2026.118552_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109394","article-title":"Degradation of CCNK\/CDK12 is a druggable vulnerability of colorectal cancer","volume":"36","author":"Dieter","year":"2021","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.bmc.2026.118552_bb0600","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","article-title":"Rational discovery of molecular glue degraders via scalable chemical profiling","volume":"16","author":"Mayor-Ruiz","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2026.118552_bb0605","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59994","article-title":"Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation","volume":"9","author":"Lv","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2026.118552_bb0610","unstructured":"Douglas T., Francis F., Christopher Roland W., et al. Pyrazole compounds as cullin ring ubiquitin ligase compounds. WO 2025\/104236, 2025-05-22."},{"issue":"10","key":"10.1016\/j.bmc.2026.118552_bb0615","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2026.118552_bb0620","unstructured":"Joseph B., Fournet G., Dumontet C., et al. Antibody-drug conjugates based on molecular glue degraders and uses thereof. WO 2025\/045758, 2025-03-06."},{"key":"10.1016\/j.bmc.2026.118552_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol Ther"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:24:47Z","timestamp":1770830687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":125,"alternative-id":["S0968089626000088"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118552","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of CDK12: a medicinal chemistry perspective","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118552"}}